Company Filing History:
Years Active: 2023-2024
Title: Innovations of Shushan Lin in Metabolic Disease Treatment
Introduction
Shushan Lin is a prominent inventor based in Dongguan, China. He has made significant contributions to the field of biotechnology, particularly in the development of fusion proteins aimed at treating metabolic diseases. With a total of 2 patents, Lin's work focuses on innovative solutions to improve health outcomes.
Latest Patents
Lin's latest patents include groundbreaking inventions such as "Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin." This patent describes a fusion protein that contains GLP-1 and FGF21 linked through an immunoglobulin Fc portion. Each of these components can be substituted with analogues or variants, and the Fc portion, which can be derived from IgG4, may include substitutions that enhance the fusion protein's stability and activity. The clinical applications of this fusion protein are promising, as it can be used to reduce glucose and lipid levels as well as body weight. Another notable patent is "FGF21 variant, fusion protein and application thereof," which highlights a fibroblast growth factor 21 (FGF21) variant that significantly improves binding ability with the target, offering potential treatments for metabolic diseases.
Career Highlights
Shushan Lin is currently associated with Sunshine Lake Pharma Co., Ltd., where he continues to innovate in the field of biotechnology. His work is characterized by a commitment to developing effective treatments for metabolic disorders, showcasing his expertise and dedication to improving patient health.
Collaborations
Lin collaborates with talented individuals such as Chao Chen and Yu Meng Li, who contribute to his research and development efforts. Their combined expertise enhances the potential for successful innovations in the field.
Conclusion
Shushan Lin's contributions to the development of fusion proteins represent a significant advancement in the treatment of metabolic diseases. His innovative patents and collaborative efforts position him as a key figure in biotechnology, with the potential to impact health outcomes positively.